Therapeutically, anti-CTLA-4 monoclonal antibodies, such as ipilimumab and tremelimumab, enhance anti-tumor immunity by blocking inhibitory CTLA-4 signals, and thereby restore T-cell effector function and increase CD28-mediated costimulation [66,67,68,69,70]. Here, CD28 is linked to neoplasm.